CVS Health (NYSE:CVS), a leading integrated healthcare and pharmacy solutions provider, released its fourth-quarter 2024 ...

CVS Health (NYSE:CVS – Free Report) had its price target lifted by JPMorgan Chase & Co. from $80.00 to $81.00 in a report ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

Equities researchers at Leerink Partnrs increased their Q1 2025 earnings estimates for shares of CVS Health in a research report issued on Wednesday, February 12th. Leerink Partnrs analyst M. Cherny ...

As healthcare spending continues to rise and regulatory pressure intensifies, companies like CVS Health CVS find themselves ...

Shareholders will be ecstatic, with their stake up 22% over the past week following CVS Health Corporation's (NYSE:CVS) ...

CVS Health posted Q4 sales of $97.71B, with a 23.3% rise in Health Care Benefits revenue. Fiscal 2025 adjusted EPS guidance ...

Sees FY25 free cash flow $6.5B. The company said, “The Company issued its full-year 2025 GAAP diluted EPS guidance range of $4.58 to $4.83 and ...

Adjusted EPS of $1.19 decreased from $2.12 in the prior year, beating the consensus of $0.93, primarily due to a decline in ...

Reports Q4 revenue $97.7B, consensus $96.88B. The company said, “Our integrated model allows us to uniquely deliver a simpler, connected ...

CVS Health's adjusted EPS beat estimates at $1.19, surpassing the expected $0.91. Revenue increased to $97.7 billion, exceeding expectations and reflecting a growth of 4.2% year-over-year.